Tea polyphenols

About us
Green tea extract
civilization of tea
Herb extract
Biochemistry products
Chinese herb
Material base
Equipment
E-shopping
corona-fz@263.net
Chinese
BIG5

 

DOSAGE OF THE CHINESE ANTICANCER HERBAL

PART A PART B PART C
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Pingying: Ningxia Gouqi
English: Barbary Wolfberry
Latin:Lycium barbarum L

Sources:The fruit of Lycium barbarum L. Family Solanaceae.

Constituents: Containing mamy kinds of amino acids, betaine, physalien, guanidine derivative, carotion, B2, niacin, cinnamic acid, the main composition of anti-cancer is Lycium barbarum polysaccharides (LBP).

Actions:
The herb has a inhibitory rate above 90% against human cervial carcinoma cell line JTC-26. Test in vivo, showed that daily dose of LBP 10 or 20mg/kg for 7 days inhibited S180 tumor growth by 31% or 39% on mice. Combination with CTX and LBP increased the inhibiting action on tumor (S180) weight about three folds over than that of CTX alone , i. e. 54% and 14%, respectively. The results showed that LBP and CTX have remarkable cooperative effect. In addition, LBP has a radiosensitizing action against Lewis lung carcinoma on mice.

Indications: It was used for treatment of intestine, stomach, pancreatic cancer, osteoma and leukemia etc.

A randomized and control clinical trial of LBP as radiosensitizing agent has been completed. There 61 cases of inoprable primary lung cancer in the trial. The focus of primary cancer was exposed by R-ray of 60Co with a dose of 60 or 70 Gy per 6 or 7 weeks, 5 times per week. In order to observe change of the focus, the patients were taken chest radiography. The 52 cases divided into two groups that were radiotherapy alone group and radiotherapy combined with LBP group. At 2 hours before exposure of R-ray, LBP of 150mg was taken 5 times weekly. 52 cases could be evaluated, for the combined therapeutic group: the CR, PR, S and total responsive rates rate were 50% (13 cases) and 92.3% and for the single radiotherapeutic group, the CR, PR, S and total responisive rates were 50% (13 cases), 42.3% (11 cases), 7.3% (2 cases) and 92.3% and for the single radiotherapeutic group, the CR, PR, S and total responisive rates were 26.9% (7 cases), 30.8% (8 cases), 42.3% (11 cases) and 57.5% respectively. The contrast between the two groups has remarkable difference (P<0.01). The results showed that LBP possessed obviously radiosensitizing effect. In the therapy, LBP has no obviously toxic or side actions. Only in a few patients the xerosis of nose mucous membrane was found, occasionally has oppilation and nosebleed. To decrease the dosage of LBP, above symptoms could be spontaneously vanished.

  
 

All Copy: FuZhou Corona Science & Technology Development Co.,Ltd.
Head Office Tel:  86-591-8376-9772 ;  8376-9751    Fax:  86-591-8376-9723
Copyright© 2001-2008 All right reserved